Multivariate proportional hazards analysis
. | . | Event-free survival . | . | . | Survival . | ||
|---|---|---|---|---|---|---|---|
. | %* . | HR . | P . | HR . | P . | ||
| PR, MS, and MF versus other | 37 | 2.41 | < .001 | 1.98 | .004 | ||
| Any cytogenetic abnormalities | 38 | 1.60 | .014 | 1.98 | .005 | ||
| β2-microglobulin level of 339 nM or higher | 44 | 1.47 | .061 | 1.55 | .092 | ||
| LDH level of 190 μ/L or higher | 34 | 169 | .011 | 1.94 | .009 | ||
. | . | Event-free survival . | . | . | Survival . | ||
|---|---|---|---|---|---|---|---|
. | %* . | HR . | P . | HR . | P . | ||
| PR, MS, and MF versus other | 37 | 2.41 | < .001 | 1.98 | .004 | ||
| Any cytogenetic abnormalities | 38 | 1.60 | .014 | 1.98 | .005 | ||
| β2-microglobulin level of 339 nM or higher | 44 | 1.47 | .061 | 1.55 | .092 | ||
| LDH level of 190 μ/L or higher | 34 | 169 | .011 | 1.94 | .009 | ||
n = 255 (of 256 patients); 1 patient is missing cytogenetics. There were 115 progression events and 74 deaths. The following variables were not significant: (1) with the sample of 255, age of 65 years or older was not significant in either analysis (P = .07 for EFS); (2) C-reactive protein level of 4 or higher; and (3) albumin level of 3.5 g/dL or less.
This column refers to the percentage of 255 cases having the incidence of each clinic feature specified in the first column of each row.